23046-68-6

Upstream product

• 50-00-0 formaldehyd 
• 942-26-7 5-chlorotryptamine hydrochloride 
• 16502-01-5 tetrahydrobetacarboline 
• 298-12-4 Glyoxilic acid 

Downstream Products

• 107889-94-1 6-Chloro-2-(2-pyridin-4-yl-ethyl)-2,3,4,9-tetrahydro-1H-β-carboline 
• 361202-25-7 8-amino-6-chloro-β-carboline 

Relevant academic research and scientific papers

Catalytic Enantioselective Synthesis of Spirooxindoles by Oxidative Rearrangement of Indoles

Oxidative rearrangement of indoles to access oxindoles has been used as a key step in complex molecule synthesis. We report a catalytic enantioselective variant of this transformation by chiral phosphoric acid catalysis, providing rapid access to a range of enantioenriched spirooxindoles. The high enantioselectivity is controlled by dynamic kinetic resolution.

Aromatic heterocyclic derivative and application thereof in medicine

The invention provides aromatic heterocyclic derivatives or stereoisomers, tautomers, nitrogen oxides, solvates, metabolites, pharmaceutically acceptable salts or prodrugs thereof, which are used for treating Alzheimer's disease. The invention also discloses pharmaceutical compositions containing the compounds and a method for treating Alzheimer's disease by using the compounds or the pharmaceutical compositions provided by the invention.

Design and synthesis of furyl/thineyl pyrroloquinolones based on natural alkaloid perlolyrine, lead to the discovery of potent and selective PDE5 inhibitors

Based on perlolyrine (1), a natural alkaloid with weak PDE5 potency from the traditional Chinese aphrodisiac plant Tribulus terrestris L., a series α-substituted tetrahydro-β-carboline (THβC) derivatives were synthesized via T+BF4--mediated oxidative C–H functionalization of N-aryl THβCs with diverse potassium trifluoroborates. Following Winterfeldt oxidation afforded the corresponding furyl/thienyl pyrroloquinolones, of which 5-ethylthiophene/ethylfuran derivatives 20a–b were identified as the most potent and selective PDE5 inhibitors. Among the enantiomers, (S)-20a and (S)-20b (IC50 = 0.52 and 0.39 nM) were found to be more effective than their (R)-antipode, display favorable pharmacokinetic profiles, exert in vitro vasorelaxant effects on the isolated thoracic aorta, and exhibit in vivo efficacy in the anesthetized rabbit erectile model.

Oxidative Rearrangement Coupling Reaction for the Functionalization of Tetrahydro-β-carbolines with Aromatic Amines

The observation of an unexpected oxidative rearrangement coupling reaction led to the development of a novel method for the efficient functionalization of tetrahydro-β-carbolines (THβCs). The treatment of THβCs with photogenerated singlet oxygen (1O2) afforded unstable dioxetanes, which underwent further transformation to form new bonds in the presence of trifluoroacetic acid. This operationally simple protocol exhibits broad functional-group tolerance and is suitable for the late-stage functionalization of complex druglike molecules.

Improving the stability and catalyst lifetime of the halogenase RebH by directed evolution

We previously reported that the halogenase RebH catalyzes selective halogenation of several heterocycles and carbocycles, but product yields were limited by enzyme instability. Here, we use directed evolution to engineer an RebH variant, 3-LR, with a Topt over 5-°C higher than that of wild-type, and 3-LSR, with a Tm 18-°C higher than that of wild-type. These enzymes provided significantly improved conversion (up to fourfold) for halogenation of tryptophan and several non-natural substrates. This initial evolution of RebH not only provides improved enzymes for immediate synthetic applications, but also establishes a robust protocol for further halogenase evolution. Evolving halos: We have used directed evolution to engineer an RebH halogenase variant with a Topt more than 5-°C higher than that of wild-type RebH, and a second variant with a Tm 18-°C higher. These enzymes provided significantly improved conversion for halogenation of tryptophan and several non-natural substrates.

PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS

The present invention provides compounds of Formula (I) including tautomers, resolved enantiomers, resolved diastereomers, solvates, metabolites, salts and pharmaceutically acceptable prodrugs thereof. Also provided are methods of using the compounds of this invention as Akt protein kinase inhibitors and for the treatment of Akt-mediated diseases, for example, hyperproliferative diseases such as cancer.

INDAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF

The present invention can provide a cancer treatment drug containing, as an active ingredient, a substance selected from the group consisting of an indazole compound of the following formula (I), a pharmaceutically acceptable salt, a hydrate, a water adduct and a solvate:

Synthesis of C-14-labeled novel IKK inhibitor: 2-[14C]-N-(6- chloro-9H-pyrido [3,4-b]indol-8-yl)-3-pyridinecarboxamide

2-[14C]-N-(6-Chloro-9H-pyrido [3,4-b]indol-8-yl)-3- pyridinecarboxamide (9A, also referred to as [14C]-PS-1145) was synthesized from [14C]-paraformaldehyde in five steps in an overall radiochemical yield of 15%. The key intermediate 1-[14C]-6-chloro-1, 2,3,4-tetrahydro-β-carboline was obtained by Pictet-Spengler cyclization of chlorotryptamine with [14C]-paraformaldehyde. Similar reactions were conducted with tryptamine to address the generality of the methodology. Copyright